D Anderson.jpg

Robert Langer
Co-founder, Scientific Advisor

Robert Langer is the David H. Koch Institute Professor at MIT (there are 13 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). He has written nearly 1,380 articles and has over 1,130 issued and pending patents worldwide. His many awards include the US National Medal of Science, the US National Medal of Technology and Innovation, the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize (largest US medical prize), the Wolf Prize for Chemistry, the 2014 Kyoto Prize and the Lemelson-MIT Prize, for being “one of history’s most prolific inventors in medicine.” Langer is one of the very few individuals ever elected to the National Academy of Medicine, the National Academy of Engineering, and the National Academy of Sciences.

anderson 2.png

Rox Anderson
Co-founder, Scientific Advisor

Dr. Rox Anderson graduated from MIT and received his MD degree from the joint MIT-Harvard medical program. Rox’s research led to the development of many of the non-scarring laser treatments now widely used in medicine to treat birthmarks, macular degeneration, cancer, acne, and hair removal. Rox led the team that developed the technology behind the revolutionary Fraxel® laser system which smooths wrinkles and lessens the effects of sun damage. Rox has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.


Daniel Anderson
Co-founder, Scientific Advisor

Dan received his PhD in molecular genetics from the University of California at Davis. At MIT, he pioneered the use of robotic methods for the development of smart biomaterials for use in medical devices, cell therapy, and drug delivery. In particular, the advanced drug delivery systems he has developed provide new methods for nanoparticulate and microparticulate drug delivery, non-viral gene therapy, siRNA delivery, and vaccines.


Board of Directors

Cropped Amy Schulman High Res.jpg

Amy Schulman
CEO and Executive Chair, Board of Directors

Amy Schulman is Executive Chair of Olivo Labs, and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, Lyndra, and the Whitehead Institute.


Amir Nashat
Board of Directors

As a Polaris Partner, Amir has been investing in technology breakthroughs since 2002. During this time, he has helped start companies in areas ranging from bioactive devices to stem cells to consumer devices to energy. Amir currently represents several Polaris companies as a Director including Olivo Labs, AgBiome, aTyr Pharmaceuticals, BIND Therapeutics, Fate Therapeutics, Promedior Pharmaceuticals, Scholar Rock, and Selecta Biosciences. In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof and Sun Catalytix Corporation. Prior to joining Polaris, Amir did basic research on advanced composite materials and bioactive micro-machines at UC Berkeley, and polymers and neural stem cells at MIT.


Daniel B. Dubin
Board of Directors

Dr. Daniel Dubin has served as an advisor to life sciences companies and investors for the past 16 years. Prior to working at Leerink Swann, he served as Chairman of MetaWorks, instructor of dermatology at Harvard Medical School, and member of the Clinical Executive Committee at the Brigham and Women’s Hospital. Dan also founded MEDACorp, a provider of insights on the commercial potentials of biotherapeutics and medical devices to institutional investors and life science companies. He is a board- certified dermatologist and has published over 30 manuscripts in peer-reviewed publications.